Article
Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.
Arthritis & rheumatology (Hoboken, N.J.) - 1 Oct 2023
Zheng Jie, Wheeler Eleanor, Pietzner Maik, Andlauer Till F M, Yau Michelle S, Hartley April E, Brumpton Ben Michael, Rasheed Humaira, Kemp John P, Frysz Monika, Robinson Jamie, Reppe Sjur, Prijatelj Vid, Gautvik Kaare M, Falk Louise, Maerz Winfried, Gergei Ingrid, Peyser Patricia A, Kavousi Maryam, de Vries Paul S, Miller Clint L, Bos Maxime, van der Laan Sander W, Malhotra Rajeev, Herrmann Markus, Scharnagl Hubert, Kleber Marcus, Dedoussis George, Zeggini Eleftheria, Nethander Maria, Ohlsson Claes, Lorentzon Mattias, Wareham Nick, Langenberg Claudia, Holmes Michael V, Davey Smith George, Tobias Jonathan H
Abstract excerpt
OBJECTIVE: In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors. METHODS: A genome-wide association study meta-analysis was performed of circulating sclerostin levels in 33,961 European individuals. Mendelian randomization (MR) was used to predict the causal effects of sclerostin lowering on 15...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.